Airain Ltd adds Celgene Corporation (CELG) to its portfolio

Celgene Corporation (CELG) : Airain Ltd added new position in Celgene Corporation during the most recent quarter end. The investment management firm now holds 215,902 shares of Celgene Corporation which is valued at $21,624,744 , the company said in a statement filed on May 9, 2016 with the SEC.Celgene Corporation makes up approximately 1.52% of Airain Ltd’s portfolio.

Other Hedge Funds, Including , Personal Capital Advisors Corp boosted its stake in CELG in the latest quarter, The investment management firm added 22,865 additional shares and now holds a total of 149,528 shares of Celgene Corporation which is valued at $14,976,724. Celgene Corporation makes up approx 0.69% of Personal Capital Advisors Corp’s portfolio. Trimtabs Asset Management sold out all of its stake in CELG during the most recent quarter. The investment firm sold 17,614 shares of CELG which is valued $1,765,804.Cypress Capital Management (wy) boosted its stake in CELG in the latest quarter, The investment management firm added 2,465 additional shares and now holds a total of 55,501 shares of Celgene Corporation which is valued at $5,739,358. Celgene Corporation makes up approx 7.43% of Cypress Capital Management (wy)’s portfolio.Mizuho Trust Banking Ltd. boosted its stake in CELG in the latest quarter, The investment management firm added 28,272 additional shares and now holds a total of 1,222,880 shares of Celgene Corporation which is valued at $126,458,021. Celgene Corporation makes up approx 0.40% of Mizuho Trust Banking Ltd.’s portfolio.

Celgene Corporation closed down -0.14 points or -0.14% at $100.16 with 32,10,112 shares getting traded on Friday. Post opening the session at $99.92, the shares hit an intraday low of $99.566 and an intraday high of $101.91 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Celgene Corporation reported $1.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.27. The company had revenue of $2511.60 million for the quarter, compared to analysts expectations of $2577.08 million. The company’s revenue was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 EPS.

Many Wall Street Analysts have commented on Celgene Corporation. Company shares were Reiterated by Sun Trust Rbsn Humphrey on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 147 from a previous price target of $145 .Citigroup Initiated Celgene Corporation on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $130.

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Leave a Reply

Celgene Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celgene Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.